The role of the kidneys in glucose homeostasis

A new path towards normalizing glycaemia

Ralph A Defronzo, J. A. Davidson, S. del Prato

Research output: Contribution to journalArticle

285 Citations (Scopus)

Abstract

The maintenance of normal glucose homeostasis requires a complex, highly integrated interaction among the liver, muscle, adipocytes, pancreas and neuroendocrine system. Recent studies have showed that the kidneys also play a central role in glucose homeostasis by reabsorbing all the filtered glucose, an adaptive mechanism that ensures sufficient energy is available during fasting periods. This mechanism becomes maladaptive in diabetes, however, as hyperglycaemia augments the expression and activity of the sodium-glucose cotransporter (SGLT) 2 in the proximal tubule of the kidney. As a result, glucose reabsorption may be increased by as much as 20% in individuals with poorly controlled diabetes. SGLT2 is a low-affinity, high-capacity glucose transport protein that reabsorbs 90% of filtered glucose, while the high-affinity, low-capacity SGLT1 transporter reabsorbs the remaining 10%. SGLT2 represents a novel target for the treatment of diabetes. In animal studies, SGLT2 inhibition reduces plasma glucose levels, resulting in improved β-cell function and enhanced insulin sensitivity in liver and muscle. Human studies have confirmed the efficacy of SLGT2 inhibitors in improving glucose control and reducing the A1c. Because the mechanism of SGLT2 inhibition is independent of circulating insulin levels or insulin sensitivity, these agents can be combined with all other antidiabetic classes, including exogenous insulin. Although the long-term efficacy and safety of SGLT2 inhibitors remain under study, the class represents a novel therapeutic approach with potential for the treatment of both type 2 and 1 diabetes.

Original languageEnglish (US)
Pages (from-to)5-14
Number of pages10
JournalDiabetes, Obesity and Metabolism
Volume14
Issue number1
DOIs
StatePublished - Jan 2012

Fingerprint

Homeostasis
Kidney
Glucose
Insulin Resistance
Sodium-Glucose Transport Proteins
Insulin
Muscles
Proximal Kidney Tubule
Neurosecretory Systems
Facilitative Glucose Transport Proteins
Liver
Type 1 Diabetes Mellitus
Hypoglycemic Agents
Adipocytes
Hyperglycemia
Type 2 Diabetes Mellitus
Pancreas
Fasting
Maintenance
Safety

Keywords

  • Clinical trials
  • Diabetes
  • Glucose homeostasis
  • Glycosuria
  • Hyperglycaemia
  • Kidneys
  • Renal glucose transport
  • SGLT2
  • SGLT2 inhibitors
  • Sodium-glucose cotransporters

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

The role of the kidneys in glucose homeostasis : A new path towards normalizing glycaemia. / Defronzo, Ralph A; Davidson, J. A.; del Prato, S.

In: Diabetes, Obesity and Metabolism, Vol. 14, No. 1, 01.2012, p. 5-14.

Research output: Contribution to journalArticle

@article{c93053f6bd854fd7b86f63abcd136323,
title = "The role of the kidneys in glucose homeostasis: A new path towards normalizing glycaemia",
abstract = "The maintenance of normal glucose homeostasis requires a complex, highly integrated interaction among the liver, muscle, adipocytes, pancreas and neuroendocrine system. Recent studies have showed that the kidneys also play a central role in glucose homeostasis by reabsorbing all the filtered glucose, an adaptive mechanism that ensures sufficient energy is available during fasting periods. This mechanism becomes maladaptive in diabetes, however, as hyperglycaemia augments the expression and activity of the sodium-glucose cotransporter (SGLT) 2 in the proximal tubule of the kidney. As a result, glucose reabsorption may be increased by as much as 20{\%} in individuals with poorly controlled diabetes. SGLT2 is a low-affinity, high-capacity glucose transport protein that reabsorbs 90{\%} of filtered glucose, while the high-affinity, low-capacity SGLT1 transporter reabsorbs the remaining 10{\%}. SGLT2 represents a novel target for the treatment of diabetes. In animal studies, SGLT2 inhibition reduces plasma glucose levels, resulting in improved β-cell function and enhanced insulin sensitivity in liver and muscle. Human studies have confirmed the efficacy of SLGT2 inhibitors in improving glucose control and reducing the A1c. Because the mechanism of SGLT2 inhibition is independent of circulating insulin levels or insulin sensitivity, these agents can be combined with all other antidiabetic classes, including exogenous insulin. Although the long-term efficacy and safety of SGLT2 inhibitors remain under study, the class represents a novel therapeutic approach with potential for the treatment of both type 2 and 1 diabetes.",
keywords = "Clinical trials, Diabetes, Glucose homeostasis, Glycosuria, Hyperglycaemia, Kidneys, Renal glucose transport, SGLT2, SGLT2 inhibitors, Sodium-glucose cotransporters",
author = "Defronzo, {Ralph A} and Davidson, {J. A.} and {del Prato}, S.",
year = "2012",
month = "1",
doi = "10.1111/j.1463-1326.2011.01511.x",
language = "English (US)",
volume = "14",
pages = "5--14",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - The role of the kidneys in glucose homeostasis

T2 - A new path towards normalizing glycaemia

AU - Defronzo, Ralph A

AU - Davidson, J. A.

AU - del Prato, S.

PY - 2012/1

Y1 - 2012/1

N2 - The maintenance of normal glucose homeostasis requires a complex, highly integrated interaction among the liver, muscle, adipocytes, pancreas and neuroendocrine system. Recent studies have showed that the kidneys also play a central role in glucose homeostasis by reabsorbing all the filtered glucose, an adaptive mechanism that ensures sufficient energy is available during fasting periods. This mechanism becomes maladaptive in diabetes, however, as hyperglycaemia augments the expression and activity of the sodium-glucose cotransporter (SGLT) 2 in the proximal tubule of the kidney. As a result, glucose reabsorption may be increased by as much as 20% in individuals with poorly controlled diabetes. SGLT2 is a low-affinity, high-capacity glucose transport protein that reabsorbs 90% of filtered glucose, while the high-affinity, low-capacity SGLT1 transporter reabsorbs the remaining 10%. SGLT2 represents a novel target for the treatment of diabetes. In animal studies, SGLT2 inhibition reduces plasma glucose levels, resulting in improved β-cell function and enhanced insulin sensitivity in liver and muscle. Human studies have confirmed the efficacy of SLGT2 inhibitors in improving glucose control and reducing the A1c. Because the mechanism of SGLT2 inhibition is independent of circulating insulin levels or insulin sensitivity, these agents can be combined with all other antidiabetic classes, including exogenous insulin. Although the long-term efficacy and safety of SGLT2 inhibitors remain under study, the class represents a novel therapeutic approach with potential for the treatment of both type 2 and 1 diabetes.

AB - The maintenance of normal glucose homeostasis requires a complex, highly integrated interaction among the liver, muscle, adipocytes, pancreas and neuroendocrine system. Recent studies have showed that the kidneys also play a central role in glucose homeostasis by reabsorbing all the filtered glucose, an adaptive mechanism that ensures sufficient energy is available during fasting periods. This mechanism becomes maladaptive in diabetes, however, as hyperglycaemia augments the expression and activity of the sodium-glucose cotransporter (SGLT) 2 in the proximal tubule of the kidney. As a result, glucose reabsorption may be increased by as much as 20% in individuals with poorly controlled diabetes. SGLT2 is a low-affinity, high-capacity glucose transport protein that reabsorbs 90% of filtered glucose, while the high-affinity, low-capacity SGLT1 transporter reabsorbs the remaining 10%. SGLT2 represents a novel target for the treatment of diabetes. In animal studies, SGLT2 inhibition reduces plasma glucose levels, resulting in improved β-cell function and enhanced insulin sensitivity in liver and muscle. Human studies have confirmed the efficacy of SLGT2 inhibitors in improving glucose control and reducing the A1c. Because the mechanism of SGLT2 inhibition is independent of circulating insulin levels or insulin sensitivity, these agents can be combined with all other antidiabetic classes, including exogenous insulin. Although the long-term efficacy and safety of SGLT2 inhibitors remain under study, the class represents a novel therapeutic approach with potential for the treatment of both type 2 and 1 diabetes.

KW - Clinical trials

KW - Diabetes

KW - Glucose homeostasis

KW - Glycosuria

KW - Hyperglycaemia

KW - Kidneys

KW - Renal glucose transport

KW - SGLT2

KW - SGLT2 inhibitors

KW - Sodium-glucose cotransporters

UR - http://www.scopus.com/inward/record.url?scp=83655193529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=83655193529&partnerID=8YFLogxK

U2 - 10.1111/j.1463-1326.2011.01511.x

DO - 10.1111/j.1463-1326.2011.01511.x

M3 - Article

VL - 14

SP - 5

EP - 14

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 1

ER -